WallStSmart

Regencell Bioscience Holdings Ltd (RGC)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

TEVA leads profitability with a 9.0% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 62/100 (C+).

RGC

Avoid

20

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9

TEVA

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 6/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RGC.

TEVAUndervalued (+46.3%)

Margin of Safety

+46.3%

Fair Value

$63.92

Current Price

$35.73

$28.19 discount

UndervaluedFair: $63.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RGC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

TEVA2 strengths · Avg: 9.5/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Return on EquityProfitability
21.6%9/10

Every $100 of equity generates 22 in profit

Areas to Watch

RGC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
26.9x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : RGC

The strongest argument for RGC centers on Debt/Equity.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, Return on Equity.

Bear Case : RGC

The primary concerns for RGC are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.

Key Dynamics to Monitor

RGC carries more volatility with a beta of 1.87 — expect wider price swings.

TEVA is growing revenue faster at 2.3% — sustainability is the question.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TEVA scores higher overall (62/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Regencell Bioscience Holdings Ltd

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Regal Entertainment Group, is a film exhibitor in the United States. The company is headquartered in Knoxville, Tennessee.

Visit Website →

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?